Despite treatment advances in newly diagnosed advanced stage ovarian cancer (aOC), improved outcomes are needed.
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer
Annals of Oncology | | P. Harter, F. Trillsch, A. Okamoto, A. Reuss, J.-W. Kim, M.J. Rubio-Pérez, M.A. Vardar, G. Scambia, O. Trédan, G.-B. Nyvang, N. Colombo, M. Bidziński, C. Grimm, S. Lheureux, E. Van Nieuwenhuysen, F. Heitz, R.M. Wenham, S. Nishio, M.C. Lim, G. Marquina, Ö. Altundağ, A. Bergamini, R. Sabatier, P. Wimberger, M.A. Gold, J. Sehouli, T.-W. Park-Simon, E. Kent, A. Correa, C. Aghajanian, DUO-O Investigators
Topics: ovarian-cancer, immunotherapy, chemotherapy